Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma

Webinar | March 13, 2024, 12 PM EST.

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

Lifs Sofia Wallström tar plats i EFPIA:s styrelse

Lifs vd Sofia Wallström har valts in i styrelsen för den europeiska branschorganisationen EFPIA.

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Novo Nordisk buys drug candidate in billion dollar deal

The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion doll...

Sneak Peek of ZEISS Metrology Expert Tips Season 2

The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.

Merck investerar över 70 miljarder dollar i USA

Merck & Co följer flera andra globala läkemedelsjättar och pumpar in hundratals miljarder kronor i nya produktionsanläggningar i USA.

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Bayer has cut 1,500 roles – so far

German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.

Chiesi satsar på leverinriktad genterapi

Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

Efter tullhoten – Novartis satsar 230 miljarder i USA

Den schweiziska läkemedelsjätten Novartis planerar att investera 23 miljarder dollar, motsvarande 230 miljarder kronor, under de närmaste fem åren för att utöka...

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan

Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.

Så blir svenska paviljongen vid Bio-Europe

Jättekonferensen Bio-Europe med över 5 000 deltagare äger i år för första gången rum i Stockholm – och svensk life science samlar styrkorna.

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Vår nya slang är grön!

Framställd av växtbaserade biomaterial som tex. ricinfrön, minskar den användningen av CO2 och växthusgaser.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Precision medicine centre: “Extensive activity on several fronts”

Two years ago, the Karolinska Institutet and the Karolinska University Hospital announced that they would jointly launch the Precision Medicine Centre. Medtech ...

Ytterligare läkemedelskandidat mot Alzheimers droppas

Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och...